|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
Biomarker |
BEFREE |
Collectively, our findings provide support that PAI-1 contributes to the development of inflammation in perirenal fat and correlates with the development of diabetic nephropathy in HFD-induced obesity.
|
30532990 |
2019 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation |
BEFREE |
Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy.
|
26616527 |
2016 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
Therapeutic |
RGD |
Panax notoginseng saponins protect kidney from diabetes by up-regulating silent information regulator 1 and activating antioxidant proteins in rats.
|
26712211 |
2016 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation |
BEFREE |
A meta-analysis was conducted to investigate the association between 4 G/5 G variants in the PAI-1 gene and DN susceptibility.
|
24345290 |
2014 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
Biomarker |
BEFREE |
Therefore, PAI-1R provides an additional therapeutic effect in slowing the progression of diabetic nephropathy via the protection of podocytes.
|
24443353 |
2014 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation |
BEFREE |
Using allelic comparison (4G vs. 5G), the PAI-1 -675 4G/5G polymorphism was observed to have no significant association with diabetes (REM OR 1.07, 95% CI 0.96, 1.20), DN (REM OR 1.10, 95% CI 0.98, 1.25), DR (REM OR 1.09, 95% CI 0.97, 1.22) or diabetic CAD risk (REM OR 1.07, 95% CI 0.81, 1.42), and similar results were obtained in the dominant, recessive and co-dominant models.
|
24223897 |
2013 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
Biomarker |
CTD_human |
Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
|
18682491 |
2009 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
Biomarker |
BEFREE |
The ASO also reduced expression of genes involved in matrix expansion such as fibronectin and collagen (I and IV) and an inhibitor of matrix degradation, PAI-1, in the renal cortex, contributing to significant reversal of mesangial expansion in both models of DN.
|
17554073 |
2007 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
Biomarker |
BEFREE |
ThePAI1 gene is therefore an excellent candidate gene for diabetic nephropathy.
|
17263760 |
2007 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation |
BEFREE |
The plasminogen activator inhibitor-1 (PAI-1) 4G/4G genotype influences the development of diabetic nephropathy and lupus nephritis.
|
15481848 |
2004 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
Biomarker |
RGD |
Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
|
15322501 |
2004 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
AlteredExpression |
BEFREE |
Thus progression of diabetic nephropathy may be promoted by PAI-1 upregulation mediated by the glycated albumin-induced Smad/DNA interactions.
|
15198928 |
2004 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation |
BEFREE |
Neither the PAI-1 nor the ApoE gene polymorphism contributes to the genetic susceptibility to diabetic nephropathy or retinopathy.
|
10809802 |
2000 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation |
BEFREE |
Diabetic patients with coexistence of PAI-1 4G/4G genotype and ACE D alleles had a higher incidence of diabetic nephropathy (22 vs. 7%, P = 0.012) than those with other combinations of genotypes.
|
10652041 |
2000 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation |
BEFREE |
We have examined the association of four candidate genes, angiotensin converting enzyme (ACE): insertion/deletion (I/D) polymorphism, plasminogen activator inhibitor-1 (PAI-1): 4G/5G polymorphism, decorin: 179/183/185 polymorphism and Werner syndrome helicase: C/R polymorphism, with the presence of diabetic nephropathy in Type 1 diabetic patients.
|
10495473 |
1999 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
Biomarker |
BEFREE |
These genes included (a) known regulators of mesangial cell activation in diabetic nephropathy (fibronectin, caldesmon, thrombospondin, and plasminogen activator inhibitor-1), (b) novel genes, and (c) known genes whose induction by high glucose has not been reported.
|
10026205 |
1999 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation |
BEFREE |
Using multivariate logistic regression analyses, we investigated the independent or synergistic effects of the ACE I/D and PAI-1 4G/5G polymorphisms on the development of diabetic nephropathy and macroangiopathy in 208 patients with non-insulin dependent diabetes mellitus (NIDDM) over a 15 year period.
|
9844142 |
1998 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
Biomarker |
BEFREE |
Protein and mRNA expression of TGF-beta isoforms, TGF-beta 1, -beta 2 and -beta 3, and deposition of fibronectin containing extra domain A (fibronectin EDA+) and plasminogen activator inhibitor-1 (PAI-1) were studied in human chronic glomerulonephritis and diabetic nephropathy.
|
8821830 |
1996 |